705
Views
2
CrossRef citations to date
0
Altmetric
Research Article

A new model to evaluate the long-term cost effectiveness of orphan and highly specialised drugs following listing on the Australian Pharmaceutical Benefits Scheme: the Bosentan Patient Registry

, PhD, , MSc (PHP), , BSc, , BSc(Hons), , BAppSc GradDipAppSc, , BSc, , PhD & , PhD show all
Pages 235-243 | Accepted 26 Feb 2008, Published online: 19 Feb 2010

References

  • Thereapeutic Goods Administration. Available at: http://www.tga.gov.au/2
  • Department of Health and Aged Care. 2006 Guidelines for Preparation of Submissions to the Pharmaceutical Benefits Advisory Committee (Version 4.1). Commonwealth Government of Australia, Canberra 2006
  • Department of Health and Aged Care. The Orphan Drug Program and Improving Community Access to Effective Drugs for Rare Diseases. Commonwealth Government of Australia, Canberra 2001.
  • Sudlow C, Carl C. Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis. British Medical Journal (Clinical research ed.) 2003; 326: 388–392.
  • Chapman S, Reeve E, Rajaratnam G, et al. Setting up an outcomes guarantee for pharmaceuticals: new approach to risk sharing in primary care. British Medical Journal (Clinical research ed.) 2003; 326: 707–709.
  • Lu C, Williams K, Day R, et al. Access to high cost drugs in Australia. British Medical Journal (Clinical research ed.) 2004; 329: 415–416.
  • Department of Health and Ageing. December 2003 PBAC Outcomes–Positive Recommendations. Pharmaceutical Benefits Scheme, Commonwealth Government of Australia, Canberra 2004
  • Keogh A, McNeil K, Williams T, et al. Pulmonary arterial hypertension: a new era in management. Medical Journal of Australia 2003; 178: 564–567.
  • Rubin LJ, Badesch BD, Barst RJ, et al. Bosentan treatment for pulmonary arterial hypertension. New England Journal of Medicine 2002; 346: 896–903.
  • Keogh AM, McDonald P, WIlliams T, et al. Tracleer (bosentan) for the treatment of pulmonary arterial hypertension: 6 month quality of life data. Journal of Heart and Lung Transplantation 2004;; 23: S54.
  • McLaughlin VV, Sitbon O, Badesch BD, et al. Survival with first line bosentan in patients with primary pulmonary hypertension. European Respiratory Journal 2005; 25: 1–6.
  • Wlodarczyk J, Cleland LG, Keogh AM, et al. Public funding of bosentan for the treatment of pulmonary artery hypertension in Australia: cost effectiveness and risk sharing. PharmacoEconomics 2006; 24: 903–915
  • Carapetis J, Passmore J, O'Grady K. Privacy legislation and research. Medical Journal of Australia 2002;; 177: 523.
  • Commonwealth Government of Australia. National Ethics Application Form. Available at: http://www.neaf.gov.au [accessed 10 September 2007].
  • National Health Information Management Group. Minimum Guidelines for Health Registers for Statistical and Research Purposes. Australian Institute of Health and Welfare, Canberra 2001
  • Gliklich RE, Dreyer NA. (Prepared by the Outcome DEcIDE Center (Outcome Sciences, Inc. dba Outcome), under Contract No. 290-05-0035-1.) AHRQ Publication No. 07-EHC001. Registries for Evaluating Patient Outcomes. Agency for Healthcare Research and Quality, RockvilleMD 2006, (draft released for peer review).
  • Williamson OD, Cameron PA, McNeil JJ. Medical registry governance and patient privacy. Medical Journal of Australia 2004; 181: 125–126.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.